Paul Kearney Email and Phone Number
Paul Kearney work email
- Valid
- Valid
Paul Kearney personal email
- Valid
Paul Kearney phone numbers
With over a decade of experience in biotechnology and healthcare, I am a data-driven innovation leader who works at the intersection of healthcare, data science, AI/ML and product development. I co-founded four successful biotech companies, developed and commercialized multiple products, raised over $200M in funding, and published over 100 papers and 12 patents in the fields of life sciences, molecular biology, bioinformatics, biostatistics, machine learning, and clinical research. I specialize in 0 to 1 product builds guided by market requirements. As the Chief Data Officer at Sera Prognostics, I oversee data science and data analytics, product development strategy, evidence development, and data narratives. I also support commercialization, publication, research and development activities. My passion is to address the hardest unmet clinical and societal needs through data exploration, collaboration, and persistent hard work. I am also the founder and CEO of Data Incites, a consulting group that provides world-class data science expertise and experience to life science and biotechnology companies, and a strategic advisor to AllerGenis, a company that develops precision diagnostic solutions for food allergy patients.
Sera Prognostics
View-
Chief Data OfficerSera Prognostics Sep 2021 - PresentSalt Lake City, Ut, UsOversees Data Science and Data Analytics; product development strategy; evidence development; data narratives; supports commercialization, publication, research and development activities.
-
Strategic AdvisorSera Prognostics Jan 2014 - Sep 2021Salt Lake City, Ut, UsSera Prognostics was founded to develop diagnostic tests for the early prediction of a woman’s individualized risk of premature birth, preeclampsia, and other pregnancy complications. Sera’s tests are designed to give women and their physicians the power and time to make a difference in maternal and newborn health with individualized treatment and care plans.The company has completed Its landmark Proteomic Assessment of Preterm Risk (PAPR) clinical study that clinically validated the PreTRM test as highly predictive of preterm birth early in pregnancy. To read more about this study, and its subsequent publication, see the link below.The company’s proteomic predictor of premature birth risk -- the PreTRM® Test for Risk Management-became commercially available in the U.S. in early 2016.
-
Founder And CeoData Incites Aug 2019 - PresentYour data tells a story. Data Incites is a consulting group providing world class data science expertise and experience to life science and biotechnology companies. Services include bioinformatics, biostatistics, machine learning, clinical research, data analysis, data visualization, FDA/CLIA/CAP/HIPAA regulatory support, biotechnology product development, companion diagnostics, and biomarker development. -
Strategic AdvisorAllergenis Jan 2018 - PresentHatfield, Pennsylvania, UsThe mission of AllerGenis is to develop precision diagnostic solutions that can help providers better screen, assess, and manage the well-being of millions of food allergy patients. Specializing in immunology and bioinformatics, AllerGenis created a highly multiplexed analytical platform to address the limitations of current tests and to provide a better predictor of patient response to future immunotherapy and drug treatments.The company started as a collaboration between Genisphere, a provider of the 3DNA® platform for targeted drug delivery, and Hugh Sampson, MD, of the Elliot and Roslyn Jaffe Food Allergy Institute of the Icahn School of Medicine at Mount Sinai. The solution leverages Genisphere's Luminex bead-based immunoassay technology (used to make life science and diagnostics tests more sensitive) and epitope mapping technology based on immunological research by Dr. Hugh Sampson. -
Chief Scientific OfficerIndi (Integrated Diagnostics) Nov 2009 - Jul 2018I co-founded Integrated Diagnostics (Indi) in 2009 with Leroy Hood, the founder of the Institute for Systems Biology in Seattle. We sold the company to Biodesix in summer 2018.Indi was a biotechnology company leveraging systems biology concepts and an advanced multiplexed proteomic platform to develop and commercialize high-value diagnostics. I was critical in the conception, funding, development, and commercialization of the first product (Xpresys) for lung cancer management. While there I developed the first multiplexed mass spectrometry platform for a high value diagnostic, along with many associated patents and high profile publications. Then I oversaw the translation of this novel technology into a regulated commercial laboratory providing a test used in the clinic today. However, my most important contribution was the assembly of a top management team of scientists, data analysts, laboratorians and IP experts, among others.
-
Scientific Director Of Special ProjectsInstitute For Systems Biology Feb 2008 - Dec 2009Seattle, Washington, UsI was hired by Leroy Hood in 2008 to be the Scientific Director of Special Projects with the Institute for Systems Biology. ISB is an international leader in biotechnological innovation, integrating genomic, proteomic, and bioinformatic tools for complex biological systems analysis.I was tasked with the development and completion of a $100M personalized medicine research proposal in collaboration with the University of Luxembourg. -
Vice President BioinformaticsCaprion Proteomics Jan 2001 - Jan 2008Caprion Proteomics is an internationally recognized leader in proteomics, specializing in biomarker discovery, immunotherapy target discovery, and infectious diseases research. Clients include most major pharmaceutical and biotech companies as well as the NIH.As the Vice President of Bioinformatics with Caprion, I provided vision for all aspects of study design, data analysis, statistics, interpretation, and data visualization. I was also the manager of proteomic platform technology, including the evaluation of new technologies, identification and implementation of process improvements.
-
Executive DirectorCaprion Pharmaceuticals 2004 - 2005
-
Assistant ProfessorUniversity Of Waterloo Sep 1998 - Aug 2002Waterloo, Ontario, Ca -
Vp Research And DevelopmentBioinformatics Solutions Jan 2000 - Jan 2001
Paul Kearney Skills
Paul Kearney Education Details
-
University Of TorontoBioinformatics/Computer Science -
Queen'S UniversityComputer Science
Frequently Asked Questions about Paul Kearney
What company does Paul Kearney work for?
Paul Kearney works for Sera Prognostics
What is Paul Kearney's role at the current company?
Paul Kearney's current role is Chief Data Officer @ Sera Prognostics | Machine Learning/AI Leader | Bioinformatics | Biostatistics | Personalized Medicine | Data Innovation.
What is Paul Kearney's email address?
Paul Kearney's email address is pa****@****ics.com
What is Paul Kearney's direct phone number?
Paul Kearney's direct phone number is +120657*****
What schools did Paul Kearney attend?
Paul Kearney attended University Of Toronto, Queen's University.
What are some of Paul Kearney's interests?
Paul Kearney has interest in Education, Environment, Science And Technology, Human Rights, Arts And Culture, Health.
What skills is Paul Kearney known for?
Paul Kearney has skills like Bioinformatics, Biomarkers, Diagnostics, Data Analysis, Algorithms, Entrepreneurship, Software Development, Business Planning, Research, Study Design, Biomarker Discovery, Mass Spectrometry.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial